CRISPR Therapeutics (CRSP) is up 12.3% today. Here is some analysis on what might have caused this price movement.
Analysis: The most likely driver is renewed investor optimism around CASGEVY commercial traction, combined with management highlighting a catalyst-heavy second half of 2026. The move also appears supported by better-than-expected quarterly results and a strong cash position, which can matter for biotech valuations.
Details:
Sources:
CRISPR Therapeutics, FDA, SEC, Vertex Pharmaceuticals
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$CRSP Insider Trading Activity
$CRSP insiders have traded $CRSP stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $CRSP stock by insiders over the last 6 months:
- SAMARTH KULKARNI (Chief Executive Officer) has made 0 purchases and 4 sales selling 37,134 shares for an estimated $1,851,837.
- RAJU PRASAD (Chief Financial Officer) has made 0 purchases and 3 sales selling 13,577 shares for an estimated $649,738.
- JAMES R. KASINGER (General Counsel and Secretary) has made 0 purchases and 4 sales selling 11,544 shares for an estimated $574,239.
- NAIMISH PATEL (Chief Medical Officer) has made 0 purchases and 2 sales selling 6,936 shares for an estimated $362,596.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$CRSP Hedge Fund Activity
We have seen 236 institutional investors add shares of $CRSP stock to their portfolio, and 227 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARK INVESTMENT MANAGEMENT LLC removed 1,852,684 shares (-16.4%) from their portfolio in Q2 2026, for an estimated $101,045,385
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,057,837 shares (+inf%) to their portfolio in Q2 2026, for an estimated $57,694,429
- LOOMIS SAYLES & CO L P removed 968,135 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $52,802,082
- D. E. SHAW & CO., INC. added 893,812 shares (+inf%) to their portfolio in Q2 2026, for an estimated $48,748,506
- BLACKROCK, INC. added 668,904 shares (+8.7%) to their portfolio in Q2 2026, for an estimated $36,482,024
- ORBIS ALLAN GRAY LTD removed 656,850 shares (-10.8%) from their portfolio in Q2 2026, for an estimated $35,824,599
- TWO SIGMA INVESTMENTS, LP added 505,570 shares (+34.1%) to their portfolio in Q2 2026, for an estimated $27,573,787
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$CRSP Price Targets
Multiple analysts have issued price targets for $CRSP recently. We have seen 5 analysts offer price targets for $CRSP in the last 6 months, with a median target of $80.0.
Here are some recent targets:
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $80.0 on 07/08/2026
- Silvan Turkcan from Citizens set a target price of $80.0 on 07/06/2026
- William Pickering from Bernstein set a target price of $56.0 on 05/13/2026
- Yigal Nochomovitz from Citigroup set a target price of $82.0 on 05/06/2026
- Edward Tenthoff from Piper Sandler set a target price of $110.0 on 03/17/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
